# Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma

> **NCT03695744** · PHASE2 · UNKNOWN · sponsor: **Singapore General Hospital** · enrollment: 27 (actual)

## Conditions studied

- Multiple Myeloma
- Myeloma

## Interventions

- **DRUG:** Daratumumab
- **DRUG:** Bortezomib
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT03695744
- **Lead sponsor:** Singapore General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-10-02
- **Primary completion:** 2021-09-30
- **Final completion:** 2024-04
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2023-07-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03695744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03695744, "Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT03695744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*